InternationalUSRemember you can easily switch between MIP US and MIP International at any time
Please note: On the LinkedIn and Twitter websites any comments made should be in accordance with their user terms. (LinkedIn terms and conditions, Twitter terms and conditions). Managing IP does not moderate comments and the opinions expressed are those of the individual group members only. They do not reflect those of Managing IP and Managing IP accepts no responsibility, legal or otherwise, for the accuracy or content of comments.
profile

Managing IP

ManagingIP

ManagingIP profile

RT @mdloney: SCOTUS TC Heartland v Kraft Foods Group Brands oral argument transcript is up! https://t.co/v29vEKCILp

Mar 27 2017 07:50 ·  reply ·  retweet ·  favourite
ManagingIP profile

Likely to be an important question for some applicants, with UPC due to come into force in December this year https://t.co/ASuSYUpRqd

Mar 27 2017 04:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

Don't forget to sign up for our next webinar, on IP in Asia, this Thursday at 3pm (London) https://t.co/gh3Ka8t9q1 @inoviaIP @Minesoftnews

Mar 27 2017 04:38 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements